AMX-500 is under clinical development by Amunix Pharmaceuticals and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMX-500’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMX-500 overview
AMX-500 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). The therapeutic candidate is being developed based on the PRO-XTEN technology. It is administered through intravenous route in the form of solution.
Amunix Pharmaceuticals overview
Amunix Pharmaceuticals (Amunix) is a biotechnology company that discovers and develops long-acting protein-based therapeutics. The company develops protein and peptide therapeutics. Amunix uses its proprietary technology platform XTEN, a proprietary recombinant polypeptide that consists of naturally-occurring hydrophilic amino acids. The company’s product pipeline includes VRS-317, NB1001, NB1002, BIVV-1001, BIVV-1002, AMX-268, and others. Amunix’s develops technologies based on XTEN, a hydrophilic polymer comprised of natural amino acids that can be attached to therapeutic peptides, proteins and small molecules and it offers products for the treatment of hemophilia, diabetes, short bowel syndrome, NASH, Oncology and lipodystrophy. The company partners with biotechnology and pharmaceutical companies. Amunix is headquartered in Mountain View, California, the US..
For a complete picture of AMX-500’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
